Muscarinic Antagonists Flashcards
Naturally occurring alkaloids
Atropine
Scopolamine
Semisynthetic/synthetic antagonists
- Different duration:
Homatropine and tropicamide
(shorter duration of action than atropine) - Receptor subtype selectivity:
Darifenacin and solifenacin (M3 selective but not complete)
4h Half-life
Hepatic metabolism accounts for the elimination of about half a dose.
- No CNS effect (preferred to scopolamine). Central excitation at toxic doses.
- Mydriasis and loss of accommodation of considerable duration (7-12 days)
- Tachycardia, larger doses cause progressively increasing tachycardia by blocking vagal effects on M2 receptors on the SA nodal pacemaker. (may fail in adults)
- Competitive antagonist
- Causes only mild vagal excitation
- Therapeutic dose 0.5-1 mg.
- Symptoms varies as dose changes. (Table 2. P17)
- Small doses: salivary and bronchial, sweating inhibition.
- Larger doses: pupil dilation, blockade of vagal effects on heart, increase HR, UT& GI inhibition
- Still larger doses of atropine: paralysis and coma; circulatory collapse and respiratory failure.
- Modulate gastrin-elicited histamine release and gastric acid secretion.
Scopolamine (3)
- CNS depression, euphoria (substance abuse)
- Mydriasis and loss of accommodation of considerable duration (7-12 days)
- Less vagal blocking effect than atropine.
.
Belladonna alkaloids
- treatment of parkinsonism (effective with levodopa)
- treat side effects of conventional antipsychotic drug therapy
Atropine, scopolamine
Quaternary Derivatives
Ipratropium
Tiotropium
——————
Both: given by **Inhalation*
(almost exclusive effect to mouth and airways, systemic absorption is minimal!!)
1. Lack appreciable action on the CNS
2. More potent than atropine (greater inhibitory effects on ganglionic transmission)
3. Minimal inhibitory effect on mucosilary clearance relative to atropine; lessens increased accumulation of lower airway secretions to patients with airway diseases compared to atropine.
Ipratropium bromide (4) ----------------------- Inhalation, COPD, Asthma max response over 30-90min last for 4-6h
- FDA approved for perennial and common cold-associated rhinorrhea鼻涕溢
- Treat chronic obstructive pulmonary disease
(less effective in most asthmatic patients)
-block all subtypes of muscarinic receptors
Tiotropium bromide (4) ---------------------------- SLOWER ONSET persist for 24h Administered as a dry powder. (Inhalation?? max response over 30-90min)
-Treat chronic obstructive pulmonary disease
- Longer duration of action
- Selectivity for M1 and M3 receptors (low selectivity for M2 minimizes its presynaptic effect on ACh release)
- Bronchialdilation, tachycardia, and inhibition of secretion (similar to atropine)
Absorption
- Belladonna alkaloids and the tertiary synthetic and semisynthetic derivatives: absorbed rapidly from the GI tract, enters circulation when applied locally to the mucosal surfaces, absorption from intact skin is limited
- Belladonna alkaloids quaternary ammonium derivatives: penetrate the conjunctiva less readily, central effect are lacking.
Atropine and related belladonna alkaloids and other derivatives
Umeclidinium
Aclidinium
- Atropine, related belladonna alkaloids and synthetic analogs:
reduce secretion in both upper and lower RT. Antihistamine. - Treat bronchial asthma or chronic obstructive pulmonary diseases
Disadvantage: reduce bronchial secretions. material hard to be removed => obstruction/infection
Note: Ipratropium and tiotropium administered by inhalation do not produce adverse effects on mucociliary clearance. They are used with inhalation of long-acting adrenergic receptor agonists.
Long acting, antimuscarinic agent recently approved for oral inhalation.
NONSELECTIVE for M1-M5. COMPETITIVE and REVSERSIBLE antagonism.
- In the airways it inhibits M3 receptor in the smooth muscle => bronchodilation.
- Long-term, once-daily
- For maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
- SHOULD NOT BE USED FOR ACUTE SYMPTOMS.
- Avoid coadministration with other anticholinergic-containing drugs.
Long acting, antimuscarinic agent recently approved for oral inhalation.
NONSELECTIVE for M1-M5. COMPETITIVE and REVSERSIBLE antagonism.
- In the airways it inhibits M3 receptor in the smooth muscle => bronchodilation.
- Long-term, twice-daily
- For maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Genitourinary Tract ----------------- Tolterodine, fesoterodine, trospium chloride oxybutynin solifenacin darifenacin
Muscarinic antagonists to treat overactive urinary bladder diseases.
Treat overactive urinary bladder disease: ---------------------------- Tolterodine Fesoterodine Trospium chloride (synthetic substitutes of atropine) --------------------------- Other drugs: Darifenacin Solifenacin Flavoxate
- Lower intravesicular pressure and increase capacity in the bladder.
- Reduce the frequency of contractions by antagonizing parasympathetic bladder control.
Side effects:
-dry mouth and eyes limited the tolerability of these drugs.
Oxybutynim
(marked as a transdermal system)
Lower incidence of side effects than oral immediate- or extended-release preps.